MSD gets injunction
September 3, 2012
THE Federal Court of Australia has
granted MSD’s application for an
interim injunction against Apotex
regarding the latter’s intention to
sell a generic mometasone furoate
aqueous nasal spray to compete
with MSD’s Nasonex (mometasone
furoate) Aqueous Nasal Spray in
Australia.
The injunction means that Apotex
will not be able to sell, or offer to
sell, its generic mometasone
furoate aqueous nasal spray until
the Court makes a final decision on
the infringement and validity of
MSD’s patent (this decision could
take approximately a year).
“MSD is a supporter of Australia’s
intellectual property laws which
provide certainty to companies, like
itself, that spend significant
amounts of time and money in
researching and developing
products that benefit the lives of
Australians,” MSD said in a
statement.
“For this reason we will vigorously
assert our patent through its expiry
on 26 January 2015,” MSD added.
The above article was sent to subscribers in Pharmacy Daily's issue from 03 Sep 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 03 Sep 12
